BRAF Biomarkers
News and reporting on BRAF biomarkers.
The drug, MS21, has shown preclinically to inhibit growth of tumor cells with mutations in the PI3K/PTEN/AKT pathway.
Deciphera Pharmaceuticals Begins ULK Kinase Inhibitor Study in RAS-, RAF-Mutated Cancers
The firm is evaluating the safety and preliminary efficacy of DCC-3116 both alone and with Novartis' Mekinist for metastatic, RAS- or RAF-mutated solid cancers.
Day One Biopharmaceuticals Prices $160M Initial Public Offering
The company plans to use the proceeds to advance development of its RAF inhibitor DAY-101, currently being studied in pediatric low-grade glioma.
FDA Clears IND for Kinnate Biopharma's RAF Inhibitor KIN-2787
The firm plans to begin evaluating the agent as a first-line treatment for BRAF-mutated solid cancers in a Phase I/II clinical trial slated for mid-2021.
LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign
Premium
LUNGevity hopes to streamline patient education messaging and reach lung cancer patients in underserved communities who miss out on comprehensive testing.
Mar 11, 2021
Sep 23, 2020
Novellus Raises $57M in Series C Funding
Aug 26, 2020